Archive

  • aside

    Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018

    Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related genes in tumours with progression-free…

    by
  • aside

    Invitation to a specialist investor event focusing on late-stage drugs for colorectal cancer with Redeye and Isofol Medical

    On April 10th, Redeye will organize an investor specialist event focusing on late-stage drugs aimed to treat colorectal cancer. Isofol…

    by
  • aside

    Isofol Medical has selected arfolitixorin-dose for the phase III pivotal study ISO-CC-007

    The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for an adult male) is based…

    by
  • aside

    Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®

    Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name arfolitixorin for…

    by
  • aside

    Isofol reports successful outcome from the scientific advice with the EMA

    Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines Agency (EMA) regarding its candidate…

    by
  • aside

    Isofol’s CEO, directors and employees converts stock – and employee options and subscribe shares for SEK 7 655 136

    The incentive program consisting of stock – and employee options in Isofol Medical AB, which was initiated in 2012 with…

    by
  • aside

    Positive treatment results with Modufolin® (arfolitixorin) will be published at a cancer congress (ASCO) in the US

    Prior to this year’s Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology (ASCO), the worlds leading oncology…

    by
  • aside

    Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin® agreed

    Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal cancer, has had a successful regulatory meeting with the…

    by
  • aside

    Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer

    Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin) from patients treated during 16 weeks…

    by
  • aside

    Isofol to present at the 10th Annual Biotech Showcase Conference

    January 4 2017 Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive Officer Anders Rabbe and Chief…

    by
  • aside

    Isofol attends the French-Swedish Life Science Day 2017

    The French-Swedish Life Science Day 2017 conference gathers highly innovative biotech companies from Sweden, French and Swedish life science investors…

    by
  • aside

    Isofol announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018

    Isofol Medical AB (publ) announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment has been accepted for presentation…

    by
  • aside

    Isofol appoints Gustaf Albèrt as Chief Financial Officer

    Isofol Medical AB (publ) has recruited Gustaf Albèrt as Chief Financial Officer. With extensive experience from leading financial positions, Albèrt…

    by
  • aside

    Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities

    Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin® as a rescue therapy, in…

    by
  • aside

    Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer

    Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA in preparation for the pivotal…

    by
  • aside

    From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer

    Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin® efficacy in the ISO-CC-005 study…

    by